Downloading...
Download

LABU

LABU / LABD Ratio Anchored VWAP over /under LABU LONGOn the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume profile overlaid. I wanted to analyze this to affirm the highest of prospects for the Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down. A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout through the hohg volume area and then over it beginning early November. Unusually high relative volume and volatility ramped up about the same time. I readily conclude that LABU is the buy right now with the ratio rising. It is a low beat ETF with good range due to the leveraging and high forecasts for 2024. I will make buys on LABU at regular intervals on a 60-120 minute time frame looking for the weekly lows. I will set an alert for a falling ratio on the 3H to daily chart to assess should the supertrend fade. I believe that this will be a safe low risk swing long trade.
AMEX:LABULong
by AwesomeAvani
FGEN A Biotechnology Penny running to earnings LONGFGEN has been uptrending for two weeks. In November's earnings it beat on revenue and burned less cash than projected. Another earnings report is impending. On the 30 minute chart, price has pumped 250%. The volume is okay but is not showing a rise and the price volume trend is flat. This is an unusual pattern. The mass index indicator shows hints of getting into the threshold and trigger zones. The dual TF RSI shows both low and high TF lines in the 60s. I am inclined to watch this, the price rise without corresponding volume increases seems to run against Wychoff theory. I will put it on a watch list. As a speculative penny stock with no earnings I will leave it alone until I see increased volume and volatility at earnings. Could there be some manipulation hidden behind the chart?
NASDAQ:FGEN
by AwesomeAvani
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report in November was a double beat which is good prognosis for the one upcomings. This is a risky earnings play, ROIV does not yet make money. However, because it lost less than forecasted, buyer interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00 per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%). Considering that ROIV has gained 12% this past week, 7% in the next two days is about the same trend angle. As to the call contract, I have considered 100% return as my expections for the two days before the earnings. If earnings disappoint trader expectations and price fades I will sell to close the contract. If earnings is as expected, I will roll the contract forward into the March monthly and add a bit more capital into the trade.
NASDAQ:ROIVLong
by AwesomeAvani
1
INBS pumped on earnings crush= Watching for LONG maybeINBS crush earnings and went parabolic on an earnings beat. Basically, revenues fell but with belt-tightening and good CEO actions it bled less cash than expected. The tourniquet is working. The post-earnings pump was followed by a flush to the mid-Fib 0.5 support. Trader's got their reward and called it a weekend before lunch. The chop index fell into the consolidation zone and the MACD turned bearish. See the 5 minute chart image inserted to the left. The RSI lines are about 50 maybe with a crossdown impending. I have this on watch for a reversal up. Much will depend on general market strength on Monday. Biotechnology is projected as a hot sector now. This stock was among the hottest of the day. Hoping for a bullish continuation knowing that a trend down is likewise possible.
NASDAQ:INBS
by AwesomeAvani
2
ZBH a medical device company falls on earnings beat LONGZBH is a big global medical device company. It is old school. Aluminum titanium polymers, plates screws wires. Hollywood stars are familiar as it makes the devices for leg lengthening surgery. ( shortening is easy, lengthening not so much) I am familiar because in the past I have served as a consultant for this company. It business is mainly orthopedic elective surgery in supporting orthopedic surgeons serving their patients spine straightening to braces for after a neck fracture. Not a surprise but a lot of surgeries were put off during Covid. So much that the catching up is still ongoing. This is part of the reason why healthcare and the medical technology sectors are expected to be among the hottest of 2024. So much for fundamentals, the technical analysis support for a long trade is commented on the chart. On it you can see the trend since the last earnings. ZBH reported Thursday, January 7th. with an earnings beat and a dip in preparation for a possible rip. The lunch hour of Thursday's session would be the next best time while another time is when you find another dip after you have read this. Want to trade and hedge your trade? Just take a trade in SYK and let them have a race. Cut the underperformer and use the proceeds to get more of the other. It's a very simple plan. Want a broad trade in medical technology? Take a look at XBI or leveraged LABU.
NYSE:ZBHLong
by AwesomeAvani
RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add to the mix of meds and lower their price in the competition may send RHYTHM into launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is considered to be the likely hottest sector of the year. I will look toward OTM call options for February 16th presently priced at about $200 per contract and a couple of shares shorted to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days before upcoming earnings.
NASDAQ:RYTMLong
by AwesomeAvani
1
MGNX a biotech company gets new "Outperform" LONGMGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the 15 minute chart price jumped about 12% in the past week and bounced down toward the anchored mean VWAP and is well situated for a long entry. the dual TF RSI indicator shows both lines crossing the 50 level in early bullish momentum off the bounce. It is continually hitting new past year highs at a great trend angle and is on pace to hit 400% for an annual return. There is no option play here as the volume is minimal and liquidity is absent. The all-time high is about $32 so there is plenty of room above the analyst's target over the long term. Price has moved 12X the S & P YTD certainly a sign of relative strength.
NASDAQ:MGNXLong
by AwesomeAvani
1
HRTX a biotech penny stock with 70% in two months LONGHRTX has been suggested by various trading websites as a potentially explosive penny biotech stock for 2024. It has experienced excellent price actions since an earnings beat in November. It beat the estimates; that is to say it burned about half as much cash as the analysts estimated the it would. Today it pumped 11%. Relevant articles can be found compiled on the Yahoo Finance page linked here. The chart is 120 minutes. A alpha trend indicator is shown and the supertrend since the November earnings is upward. An AI Lorentzian indicator is added with a 2000 candle lookback to generate buy and sell signals. It calculated a 59% win on 83 trades over those 2000 candles two hours each; this amounts to about 2000 x 2 / 6 hrs per session or more than 600 trading days = 2 1/2 years. Also supporting an entry at this time is the faster (45 min) RSI line rising over the 50 level while the slower ( 240 minutes in red) RSI line has been over the 50 level since those earnings. The ADX indicator had a DI- and DI + flip with a mini pullback to close out last week's trading ( profit taking). The volatility indicator also showed that dip with selling volatility greater than buying which has now flipped. Given that price has went 5X in 2 months , there is a possibility HRTX is overbought. Analysts seem to think otherwise. I will take a stock position here and anticipate holding the position into the next earnings. For trade management I will take partials of 5 % each at the high of day for ten days going into earnings and hold the remaining 50% through the earnings. In the meanwhile I will review the trade if the machine-learning alo indicator generates either a buy or sell signal. For those lacking the risk tolerance for money-losing biotechnology penny stocks with high potential but are aware that biotechnology is expected to be "outperforming" in 2024, XBI and LABU are ETFs with risk-mitigation in the form of a diverse portfolio from the sector.
NASDAQ:HRTXLong
by AwesomeAvani
LABU / LABD Medical Leveraged ETFs Flip Strategy.LABU is shown here on a 2H time frame. I am holding 500 shares having bought November 14th on golden cross of fast and slow hull moving averages. The unrealized gain is 50%. Here, I determine that I should en bloc or in increments close the position. First, on the dual time RSI indicator of Chris Moody, the RSI is now over 60 and approaching 65. Price pivoted when RSI was in this range as shown by the red down arrows on the chart. A fibonacci analysis is that the LABU downtrend of early September to late October has now retraced in the range of 50% with the mid levels shown on the chart from the drawing tool. Because of these two considerations, I believe that I should bank the 50% profit in less than 3 weeks and perhaps take a position in the inverse ETF LABD. I will do this on a 15 minute time frame, take off one fifth of the position daily at the high of day as determined by an alert for the faster Hull Moving Average doing down instead of upsloping. At the same time on the LABD 15 minute chart I will buy a corresponding position at the low of day again using an alert. By the end of the five days, the LABU position will be closed and the profits redeployed into LABD. When LABD retraces 505 of its downtrend and RSI rises above 60, I will consider fading the position and retaking a position in LABU. thus toggling positions in the inverse ETFs as analysis and indicators dictate.
AMEX:LABULong
by AwesomeAvani
1
ETON Biotech Big Earning Beat Pullback LONGETON jumped on a big earnings report a week ago. This small cap biotechology company is making big money and traders responded. It has now experienced a standard 0.5 Fib level retracement pullback and traders early in the jump take profit. At this level new buyers have equilibrated with those selling their shares and taking profit. The ZL MACD lines are ready to cross bearly under the histogram whose negative/ red amplitude is reverting toward the zero line. The lines of the dual time frame RS indicator have held above the 50 level. In consideration of this healthy pullback and buying /selling pressure equilibrium I will take a long trade looking for 15-20% upside considering also the uprising fundamentals of the stock based on the big earnings beat.
NASDAQ:ETONLong
by AwesomeAvani
8
BIOL- running earnings 8/10 LONGBIOL had a triple top in late July so this is a logical long target at 8,0, With earnings in less than two days, volumes above the mean in the past couple of days and a decent price-volume product trend coupled with a Price Monetum Oscillator without any signs of topping out in a momentum stall or fade. I see this as a long pre-earnings play with about 12% upside to the target from the current price. BIOL has no options. The last earnings were a solid cash making top and bottom line beat. Go BIOL !
BLong
by AwesomeAvani
ZYXI reverses from whipsaw volatility LONGXYNI is now ready to reverse long. I analyze this because ZYXI has dropped from overvalued and overbought through the fair value zone into undervalued territory in three trading days by viewing the anchored VWAP bands and the volume profile, The mean VWAP and POC line are confluent at 7.25. This is the logical first target. The MACD lines are negative 4X the amplitude of the the negative histogram on the 2H and impending cross. The mass index is a sensitive signal of reversal potential is about to trigger and probably has done so on lower time frames. I will take ZYXI long with a good entry to be found on a 15-30 minute the time frame when I get an alert that it has crossed over the hand-drawn resistance trend line. I am expecting 8% before the first take profit target and 12% on the overall trade over the next 5 trading days or so. A modest profit for low risk, I think. Anyone in faraway places from the Wall Street market manipulators and FDA, this one is for you.
NASDAQ:ZYXILong
by AwesomeAvani
4
IMGN Biotech Post Earnings IMGN had great earnings the last days of April and has been trending up ever since. It is riding the upper Bollinger band consistently in this past wee. The volume spike after earnings has subsided but ongoing volume is at about 5X the moving average of early April and March. Increased volume supports price momentum. The volume spike here is obvious and significant. IMGN announced a public offering. I see this as a positive. It is primed for increasing growth but needs the fuel. Interest rates are high. Stock offering will raise cash and all shareholders will be rewarded. IMGN is resting and consolidated in a narrow range during this public offering. See also the favorable article from IBD linked below. I see IMGN as a solid swing long until the next earnings. I will watch for an uncoiling upon completion of the offering with resumption of momentum moving forward.
ILong
by AwesomeAvani
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one standard deviation above VWAP while at the bottom it is bouncing from the bottom of the lower high volume area of the profile and two standard deviations below VWAP. I see this as an opportunity for a 6% upside long day trade especially if the general market is uptrending after the weekend. Alternatively, a 5 DTE call option with a strike of $ 15.50 or $16.00 looking for a 30-40% return on the premium over the upcoming week. ( The zero lag MACD confirms the buy signal.)
AMEX:LABDLong
by AwesomeAvani